Literature DB >> 10544109

Impaired antiviral response in human hepatoma cells.

P Keskinen1, M Nyqvist, T Sareneva, J Pirhonen, K Melén, I Julkunen.   

Abstract

Hepatitis B, C, and D viruses can infect liver cells and in some individuals establish a chronic phase of infection. Presently, relatively little information is available on the antiviral mechanisms in liver cells. Because no good in vitro model infection systems for hepatitis viruses are available, we have used influenza A, Sendai, and vesicular stomatitis (VSV) viruses to characterize interferon (IFN) responses and IFN-induced antiviral mechanisms in human hepatoma cell lines. HepG2 or HuH7 cells did not show any detectable IFN-alpha/beta production in response to influenza A or Sendai virus infections. Treatment of cells with IFN-alpha resulted in upregulation of IFN-alpha-inducible Mx, 2',5'-oligoadenylate synthetase (OAS) and HLA class I gene expression but only with exceptionally high levels of IFN-alpha (>/=100 IU/ml). Accordingly, high pretreatment levels of IFN-alpha, 1000 IU/ml for influenza A and VSV and 100 IU/ml for Sendai virus, were required before any detectable antiviral activity against these viruses was seen. IFN-gamma had some antiviral effect against influenza A virus but appeared to be ineffective against VSV and Sendai virus. IFN-gamma upregulated HLA class I protein expression, whereas Mx or OAS expression levels were not increased. There was a modest upregulation of HLA class I expression during Sendai virus infection, whereas influenza A virus infection resulted, after an initial weak upregulation, in a clear decrease in HLA class I expression at late times of infection. The results suggest that hepatoma cells may have intrinsically poor ability to produce and respond to type I IFNs, which may contribute to their inability to efficiently resist viral infections. Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10544109     DOI: 10.1006/viro.1999.9983

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  41 in total

1.  Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection.

Authors:  Xiaoming Cheng; Takuro Uchida; Yuchen Xia; Regina Umarova; Chun-Jen Liu; Pei-Jer Chen; Anuj Gaggar; Vithika Suri; Marcus M Mücke; Johannes Vermehren; Stefan Zeuzem; Yuji Teraoka; Mitsutaka Osawa; Hiroshi Aikata; Keiji Tsuji; Nami Mori; Shuhei Hige; Yoshiyasu Karino; Michio Imamura; Kazuaki Chayama; T Jake Liang
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

2.  An Improved Reverse Genetics System to Overcome Cell-Type-Dependent Ebola Virus Genome Plasticity.

Authors:  Yoshimi Tsuda; Thomas Hoenen; Logan Banadyga; Carla Weisend; Stacy M Ricklefs; Stephen F Porcella; Hideki Ebihara
Journal:  J Infect Dis       Date:  2015-03-24       Impact factor: 5.226

3.  TRIM56 is an essential component of the TLR3 antiviral signaling pathway.

Authors:  Yang Shen; Nan L Li; Jie Wang; Baoming Liu; Sandra Lester; Kui Li
Journal:  J Biol Chem       Date:  2012-09-04       Impact factor: 5.157

4.  Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages.

Authors:  Xiaoming Cheng; Yuchen Xia; Elisavet Serti; Peter Daniel Block; Michelle Chung; Kazuaki Chayama; Barbara Rehermann; T Jake Liang
Journal:  Hepatology       Date:  2017-12       Impact factor: 17.425

5.  Overlapping and distinct molecular determinants dictating the antiviral activities of TRIM56 against flaviviruses and coronavirus.

Authors:  Baoming Liu; Nan L Li; Jie Wang; Pei-Yong Shi; Tianyi Wang; Mark A Miller; Kui Li
Journal:  J Virol       Date:  2014-09-24       Impact factor: 5.103

6.  Dynamic oscillation of translation and stress granule formation mark the cellular response to virus infection.

Authors:  Alessia Ruggieri; Eva Dazert; Philippe Metz; Sarah Hofmann; Jan-Philip Bergeest; Johanna Mazur; Peter Bankhead; Marie-Sophie Hiet; Stephanie Kallis; Gualtiero Alvisi; Charles E Samuel; Volker Lohmann; Lars Kaderali; Karl Rohr; Michael Frese; Georg Stoecklin; Ralf Bartenschlager
Journal:  Cell Host Microbe       Date:  2012-07-19       Impact factor: 21.023

7.  Gene expression and antiviral activity of alpha/beta interferons and interleukin-29 in virus-infected human myeloid dendritic cells.

Authors:  Pamela Osterlund; Ville Veckman; Jukka Sirén; Kevin M Klucher; John Hiscott; Sampsa Matikainen; Ilkka Julkunen
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

8.  Cytopathic and noncytopathic interferon responses in cells expressing hepatitis C virus subgenomic replicons.

Authors:  Ju-Tao Guo; Qing Zhu; Christoph Seeger
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

9.  Responses of nontransformed human hepatocytes to conditional expression of full-length hepatitis C virus open reading frame.

Authors:  Weiliang Tang; Catherine A Lázaro; Jean S Campbell; W Tony Parks; Michael G Katze; Nelson Fausto
Journal:  Am J Pathol       Date:  2007-11-08       Impact factor: 4.307

10.  The Molecular Chaperone GRP78 Contributes to Toll-like Receptor 3-mediated Innate Immune Response to Hepatitis C Virus in Hepatocytes.

Authors:  Dahai Wei; Nan L Li; Yanli Zeng; Baoming Liu; Kattareeya Kumthip; Tony T Wang; Dezheng Huo; Jesse F Ingels; Lu Lu; Jia Shang; Kui Li
Journal:  J Biol Chem       Date:  2016-04-20       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.